|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We show that deficient IL-18 production occurs at initial inflammation stages of disease, and that IL-1β production is more significantly impaired in Casp11<sup>-/-</sup> colons during established CAC.
|
30538296 |
2019 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In this study, we investigated IL-18 expression and its correlation with patient survival and immune cell infiltration in melanoma using cancer gene expression data publicly available through various databases.
|
31731729 |
2019 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
There is convincing evidence that IL-18 plays an important role in various pathologies (i.e. inflammatory diseases, cancer, chronic obstructive pulmonary disease, Crohn's disease and others).
|
31753718 |
2019 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Interleukin-18 (IL-18) is a multifunctional cytokine that augments interferon-γ production and acts as an important immunomediator in the development of several types of cancer.
|
30464617 |
2018 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Inflammasomes, which are intracellular multi-protein complexes, promote acute and chronic inflammation via interleukin-1β or interleukin-18 maturation, and they are known targets for metabolic syndromes and cancer.
|
27133472 |
2018 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Short- and long-term administration of interleukin-18 appeared to have no adverse effects on the kidney in these mice, suggesting that administration may be a safe and novel treatment for metabolic diseases and cancer.
|
29514661 |
2018 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Here, we demonstrate that interleukin-18 (IL-18)-secreting CAR T cells exhibit enhanced in vivo expansion and persistence and significantly increase long-term survival in syngeneic mouse models of both hematological and solid malignancies.
|
29768210 |
2018 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
No consensus exists on the impact of polymorphisms in cytokines (such as interleukin IL-8 and IL-18) on cancer risk; moreover, there is very little evidence regarding head and neck cancer (HNC).
|
30127645 |
2018 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Further studies of rhIL-18 and CD20 monoclonal antibodies in B-cell malignancies are warranted.
|
29517616 |
2018 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We made the following important findings: (1) Caspase-1 exerts its regulatory effects on the majority of genes in a tissue-specific manner; (2) Caspase-1 regulatory genes partially cooperates with genes regulated by sirtuin-1 during organ injury and inflammation in adipose tissue but not in the liver; (3) Caspase-1 cooperates with IL-1β in regulating less than half of the genes involved in cardiovascular disease, organismal injury, and cancer in mouse liver; (4) The meta-analysis identifies 40 caspase-1 globally regulated genes across tissues, suggesting that caspase-1 globally regulates many novel pathways; and (5) The meta-analysis identified new cooperatively and non-cooperatively regulated genes in caspase-1, IL-1β, IL-18, and Sirt-1 pathways.
|
28153032 |
2017 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Inhibition of IL-18-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy against osteosarcoma cancer.
|
29226090 |
2017 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In this article, we aimed to present an updated review on these aspects regarding the contribution of IL-18 to important diseases such as cancer, autoimmunity, and inflammatory-mediated conditions including allergic diseases, metabolic syndrome, and atherosclerosis.
|
29478963 |
2017 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Activated NLRP3 inflammasome induces the maturation of its effector cytokine IL-18 which functions in the development of cancer.
|
29312552 |
2017 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
While the inflammatory cytokine interleukin-18 (IL-18) is known to activate natural killer (NK) cells, its precise role in cancer is controversial.
|
28415798 |
2017 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Several lines of evidence suggests that in cancer the inflammasome is positively associated with characteristics such as elevated levels of IL-1β and IL-18, activation of NF-κB signaling, enhanced mitochondrial oxidative stress, and activation of autophagic process.
|
27206676 |
2016 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The current meta-analysis suggests that the -607C/A polymorphism in IL-18 gene promoter is associated with a significantly increased risk of cancer, especially of breast cancer, nasopharyngeal carcinoma and esophageal cancer and in Asian and Mixed populations.
|
26214646 |
2015 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Increased IL-18 levels in the serum of cancer patients correlated with malignancy, and IL-18 acts a crucial factor for cell migration in gastric cancer and melanoma.
|
25727011 |
2015 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
An inappropriate production of interleukin-18 (IL-18) contributes to the pathogenesis of malignancies and may influence the clinical outcome of patients.
|
25776473 |
2015 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
However, the dual role of IL-18 in different experimental tumor models and human cancers raises critical issues on its therapeutic use in cancer.
|
25548255 |
2015 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Circulating IL-18 levels were significantly elevated in cancer and BPH patients carrying GG genotypes for -137 of IL-18.
|
25892571 |
2015 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Interleukin-18 (IL-18) is a key cytokine responsible for immune response and involved in the process of cancer development.
|
24898701 |
2014 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A novel cancer vaccine strategy with combined IL-18 and HSV-TK gene therapy driven by the hTERT promoter in a murine colorectal cancer model.
|
25051201 |
2014 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Single nucleotide polymorphisms in the promoter region of interleukin-18 (IL-18), an inflammatory cytokine, have been linked to susceptibility to many diseases, including cancer and immune dysfunction.
|
23739747 |
2013 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The association of -137G>C polymorphism in the promoter region of IL-18 with cancer risk is still elusive based on current genetic association studies.
|
23794112 |
2013 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The present meta-analysis suggests that the -607C/A polymorphisms in IL-18 gene promoter is associated with a significantly increased risk of cancer, especially for nasopharyngeal carcinoma and esophageal cancer and in Asian population.
|
24130810 |
2013 |